Special Issue "Cytomegalovirus Infection and Cytomegalovirus Vaccine"
Deadline for manuscript submissions: 28 February 2022.
Interests: endocytosis; endosomal system; endosomal recycling; cytomegalovirus; assembly compartment; murine cytomegalovirus secondary envelopment and egress
Human cytomegalovirus (HCMV) is a widespread herpesvirus that infects most of the human population. In immunocompetent individuals, the infection is asymptomatic, but the virus remains in the lifelong latent state from which reactivation may occur. In immunocompromised people and congenitally infected children, it can cause severe and life-threatening conditions. However, its lifelong persistence and occasional reactivation may also be associated with various pathophysiological conditions in normal individuals. Thus, the development of a vaccine against HCMV is considered a priority in the scientific community. However, the progress toward a vaccine for HCMV has been slow. It appears that additional knowledge about the biology of the virus, its interaction with host cells and the immune system, and the pathophysiology of CMV infection is required for the progress. This knowledge is also essential for vaccine development strategies and should be aligned with the progress in the vaccine development field, such as recent progress in vector vaccines or mRNA vaccines. In order to move towards these goals, alignment with additional studies related to many public health issues is necessary, such as identifying the target population for vaccination, the proper way of vaccination to establish an effective vaccination schedule, and the development of natural models to test vaccination strategies. Thus, this Special Issue aims to collect original research and review articles which can elucidate molecular and biochemical mechanisms of all aspects of CMV pathophysiology and vaccine development.
Topics of interest for this Special Issue include, but are not limited to, molecular studies of:
- CMV biology and CMV gene products;
- Cell biology of CMV infection;
- Interactions of CMV with host cells and exploitation of the host-cell machinery for virus replication after acute infection and reactivation from latency;
- Cytopathogenic effects of acute and latent CMV infection;
- High-throughput studies of virus–host interaction;
- Experimental models of CMV infection;
- Pathophysiology of CMV infection;
- CMV immune evasion mechanisms;
- CMV vaccine development and vaccination strategies.
Dr. Pero Lucin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- virus–host interaction
- CMV assembly
- CMV replication cycle
- CMV immunization
- CMV vaccine
- CMV DNA-based vaccine
- CMV RNA-based vaccine
- subunit vaccine